Vaporox has developed a patented and FDA-cleared technology called Vaporous Hyperoxia Therapy (VHT™), which accelerates the healing of 9 different types of wounds. For Example, chronic diabetic foot ulcers (DFUs), which are both painful and debilitating, generate annual healthcare costs around $15 billion/year in the U.S. alone. DFUs are the leading cause of non-traumatic lower extremity amputations in the US.
Vaporox’s technology, Vaperous Hyperoxia Therapy (“VHT”) is a breakthrough technology for healing skin wounds. VHT employs ultrasonic waves to create an aqueous vapor containing an antimicrobial. VHT penetrates into the recesses of the wound, and ultimately through the cell walls. VHT is both much more effective and more comfortable for patients than existing treatments. In a clinical study, VHT healed 87% of diabetic foot ulcers (DFUs) that had defied the current “gold standard” of wound care.